Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: AP4S1 (ImmuneEditome ID:11154)

1. Gene summary of enriched editing regions for AP4S1

Gene summary

Gene information	Gene symbol	AP4S1
	Gene ID	11154
	GeneSynonyms	AP47B\|CLA20\|CLAPS4\|CPSQ6\|SPG52
	GeneCytomap	14q12
	GeneType	protein-coding
	GeneDescription	AP-4 complex subunit sigma-1\|AP-4 adapter complex subunit sigma-1\|AP-4 adaptor complex subunit sigma-1\|adaptor related protein complex 4 sigma 1 subunit\|clathrin-associated/assembly/adaptor protein, sigma 4\|sigma-4-adaptin
	GeneModificationdate	20230329
	UniprotID	Q9Y587;A0A5F9ZI62;A0A5F9ZHV3;G3V4P7;A0A8C8KCP6;A0A5F9ZH42;A0A8C8KBR5
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr14:31085543-31085724:+	ENST00000216366.7	ENSG00000100478.13	AP4S1	UTR3	AluJr	chr14:31085543-31085724:+.alignment
chr14:31085543-31085724:+	ENST00000554345.4	ENSG00000100478.13	AP4S1	UTR3	AluJr	chr14:31085543-31085724:+.alignment
chr14:31093482-31096121:+	ENST00000542754.5	ENSG00000100478.13	AP4S1	UTR3	FAM,AluSz,AluSz6,AluSx,AluJo,AluJr,AluJb	chr14:31093482-31096121:+.alignment
chr14:31093482-31096121:+	ENST00000616371.3	ENSG00000100478.13	AP4S1	UTR3	FAM,AluSz,AluSz6,AluSx,AluJo,AluJr,AluJb	chr14:31093482-31096121:+.alignment
chr14:31093482-31096121:+	ENST00000622409.3	ENSG00000100478.13	AP4S1	UTR3	FAM,AluSz,AluSz6,AluSx,AluJo,AluJr,AluJb	chr14:31093482-31096121:+.alignment

Top

2. Tumor-specific enriched editing regions for AP4S1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr14:31093482-31096121:+	BRCA	EER	1.9816e-06
ENSG00000100478.13,AP4S1	BRCA	EAG	2.0891e-06
chr14:31093482-31096121:+	HNSC	EER	1.0267e-02
ENSG00000100478.13,AP4S1	HNSC	EAG	1.0499e-02
chr14:31093482-31096121:+	KIRC	EER	2.3305e-06
ENSG00000100478.13,AP4S1	KIRC	EAG	2.6530e-06
chr14:31093482-31096121:+	KIRP	EER	2.6591e-04
ENSG00000100478.13,AP4S1	KIRP	EAG	2.5969e-04
chr14:31093482-31096121:+	LUSC	EER	3.5943e-02
ENSG00000100478.13,AP4S1	LUSC	EAG	3.9626e-02
chr14:31093482-31096121:+	PRAD	EER	1.7781e-02
ENSG00000100478.13,AP4S1	PRAD	EAG	1.7133e-02
chr14:31093482-31096121:+	THCA	EER	5.5466e-24
ENSG00000100478.13,AP4S1	THCA	EAG	6.1269e-24
chr14:31093482-31096121:+	UCEC	EER	3.7137e-04
ENSG00000100478.13,AP4S1	UCEC	EAG	2.7205e-04

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000100478.13,AP4S1	KIRC	Path	EAG	3.1112e-05	1.7398e-05	0.1969
chr14:31093482-31096121:+	KIRC	Path	EER	4.3012e-05	2.9598e-05	0.1918
ENSG00000100478.13,AP4S1	PAAD	Path	EAG	3.3078e-02	4.4589e-03	0.2357
chr14:31093482-31096121:+	PAAD	Path	EER	3.2903e-02	4.4753e-03	0.2364
ENSG00000100478.13,AP4S1	THCA	Path	EAG	3.2785e-06	7.0414e-04	0.1513
chr14:31093482-31096121:+	THCA	Path	EER	2.9226e-06	6.6224e-04	0.1521

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for AP4S1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr14:31093482-31096121:+

LGG

EER

ENSG00000100478,AP4S1

-0.5622

4.8998e-39

4.6445e-43

-0.5517

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2

Macrophages_M2

GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

chr14:31093482-31096121:+

LGG

EER

ENSG00000197102,DYNC1H1

-0.5176

1.7715e-31

2.2916e-36

-0.5121

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr14:31093482-31096121:+

LGG

EER

ENSG00000066739,ATG2B

-0.4956

5.0705e-28

2.3513e-29

-0.4641

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr14:31093482-31096121:+

LGG

EER

ENSG00000178974,FBXO34

-0.4873

5.0705e-28

3.6134e-26

-0.4396

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_SPERMATOGENESIS

chr14:31093482-31096121:+

LGG

EER

ENSG00000257647,RP11-701H24.3

-0.4891

1.4104e-27

5.4643e-26

-0.4381

DKC1;ELAVL1

Macrophages_M2

GSVA_HALLMARK_DNA_REPAIR

chr14:31093482-31096121:+

LGG

EER

ENSG00000151320,AKAP6

-0.4609

5.2044e-26

6.2467e-27

-0.4456

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr14:31093482-31096121:+

LGG

EER

ENSG00000198718,FAM179B

-0.4707

2.4452e-25

3.3991e-27

-0.4477

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_UV_RESPONSE_DN

chr14:31093482-31096121:+

LGG

EER

ENSG00000103657,HERC1

-0.4620

8.7623e-25

5.4000e-25

-0.4300

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_P53_PATHWAY

chr14:31093482-31096121:+

LGG

EER

ENSG00000156050,FAM161B

-0.4653

1.3664e-24

1.8192e-26

-0.4420

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;IGF2BP2;NOP56;NOP58;PTBP1;SRSF1;U2AF2

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr14:31093482-31096121:+

LGG

EER

ENSG00000133030,MPRIP

-0.4574

2.5553e-24

3.5719e-27

-0.4476

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_P53_PATHWAY

chr14:31093482-31096121:+

LGG

EER

ENSG00000100478,AP4S1

-0.5622

4.8998e-39

4.6445e-43

-0.5517

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2

Macrophages_M2

GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

chr14:31093482-31096121:+

LGG

EER

ENSG00000197102,DYNC1H1

-0.5176

1.7715e-31

2.2916e-36

-0.5121

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr14:31093482-31096121:+

LGG

EER

ENSG00000066739,ATG2B

-0.4956

5.0705e-28

2.3513e-29

-0.4641

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr14:31093482-31096121:+

LGG

EER

ENSG00000178974,FBXO34

-0.4873

5.0705e-28

3.6134e-26

-0.4396

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_SPERMATOGENESIS

chr14:31093482-31096121:+

LGG

EER

ENSG00000257647,RP11-701H24.3

-0.4891

1.4104e-27

5.4643e-26

-0.4381

DKC1;ELAVL1

Macrophages_M2

GSVA_HALLMARK_DNA_REPAIR

chr14:31093482-31096121:+

LGG

EER

ENSG00000151320,AKAP6

-0.4609

5.2044e-26

6.2467e-27

-0.4456

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr14:31093482-31096121:+

LGG

EER

ENSG00000198718,FAM179B

-0.4707

2.4452e-25

3.3991e-27

-0.4477

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_UV_RESPONSE_DN

chr14:31093482-31096121:+

LGG

EER

ENSG00000103657,HERC1

-0.4620

8.7623e-25

5.4000e-25

-0.4300

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_P53_PATHWAY

chr14:31093482-31096121:+

LGG

EER

ENSG00000156050,FAM161B

-0.4653

1.3664e-24

1.8192e-26

-0.4420

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;IGF2BP2;NOP56;NOP58;PTBP1;SRSF1;U2AF2

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr14:31093482-31096121:+

LGG

EER

ENSG00000133030,MPRIP

-0.4574

2.5553e-24

3.5719e-27

-0.4476

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_P53_PATHWAY

chr14:31093482-31096121:+

LGG

EER

ENSG00000100478,AP4S1

-0.5622

4.8998e-39

4.6445e-43

-0.5517

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2

Macrophages_M2

GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

chr14:31093482-31096121:+

LGG

EER

ENSG00000197102,DYNC1H1

-0.5176

1.7715e-31

2.2916e-36

-0.5121

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr14:31093482-31096121:+

LGG

EER

ENSG00000066739,ATG2B

-0.4956

5.0705e-28

2.3513e-29

-0.4641

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr14:31093482-31096121:+

LGG

EER

ENSG00000178974,FBXO34

-0.4873

5.0705e-28

3.6134e-26

-0.4396

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_SPERMATOGENESIS

chr14:31093482-31096121:+

LGG

EER

ENSG00000257647,RP11-701H24.3

-0.4891

1.4104e-27

5.4643e-26

-0.4381

DKC1;ELAVL1

Macrophages_M2

GSVA_HALLMARK_DNA_REPAIR

chr14:31093482-31096121:+

LGG

EER

ENSG00000151320,AKAP6

-0.4609

5.2044e-26

6.2467e-27

-0.4456

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr14:31093482-31096121:+

LGG

EER

ENSG00000198718,FAM179B

-0.4707

2.4452e-25

3.3991e-27

-0.4477

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_UV_RESPONSE_DN

chr14:31093482-31096121:+

LGG

EER

ENSG00000103657,HERC1

-0.4620

8.7623e-25

5.4000e-25

-0.4300

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_P53_PATHWAY

chr14:31093482-31096121:+

LGG

EER

ENSG00000156050,FAM161B

-0.4653

1.3664e-24

1.8192e-26

-0.4420

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;IGF2BP2;NOP56;NOP58;PTBP1;SRSF1;U2AF2

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr14:31093482-31096121:+

LGG

EER

ENSG00000133030,MPRIP

-0.4574

2.5553e-24

3.5719e-27

-0.4476

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Macrophages_M2

GSVA_HALLMARK_P53_PATHWAY

More results

Top

4. Enriched editing regions and immune related splicing for AP4S1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr14:31093482-31096121:+

ESCA

EER

MEX

ENSG00000149925.12

chr16

30065875:30065927:30066049:30066083:30066884:30067038:30067233:30067290

0.2045

3.6581e-02

2.4250e-07

0.4029

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

GSVA_HALLMARK_GLYCOLYSIS

chr14:31093482-31096121:+

GBM

EER

ENSG00000214022.7

chr7

150368789:150368941:150369670:150371632:150371227:150371632

-0.3697

1.3903e-03

3.6893e-07

-0.4060

DGCR8;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

GSVA_HALLMARK_BILE_ACID_METABOLISM

ENSG00000100478.13,AP4S1

GBM

EAG

ENSG00000214022.7

chr7

150368789:150368941:150369670:150371632:150371227:150371632

-0.3699

1.5982e-03

3.6041e-07

-0.4063

AIFM1;AUH;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;MBNL2;METTL3;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;ZNF184

GSVA_HALLMARK_BILE_ACID_METABOLISM

ENSG00000100478.13,AP4S1

GBM

EAG

ENSG00000214022.7

chr7

150368789:150368941:150371227:150374044

-0.3972

8.1534e-04

2.8964e-08

-0.4300

GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

chr14:31093482-31096121:+

GBM

EER

ENSG00000214022.7

chr7

150368789:150368941:150371227:150374044

-0.3965

7.4284e-04

3.0209e-08

-0.4295

DGCR8;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

chr14:31093482-31096121:+

KIRC

EER

MEX

ENSG00000129657.10

chr17

77215922:77215948:77216062:77216166:77216231:77216296:77216335:77216348

0.1782

8.5953e-03

6.3654e-16

0.4331

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Dendritic_cells_activated

GSVA_HALLMARK_NOTCH_SIGNALING

ENSG00000100478.13,AP4S1

KIRC

EAG

MEX

ENSG00000129657.10

chr17

77215922:77215948:77216062:77216166:77216231:77216296:77216335:77216348

0.1739

1.2330e-02

7.4384e-14

0.4037

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;MBNL2;METTL3;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;WTAP;ZNF184

Dendritic_cells_activated

GSVA_HALLMARK_NOTCH_SIGNALING

chr14:31093482-31096121:+

KIRC

EER

MEX

ENSG00000129657.10

chr17

77215922:77215948:77216062:77216153:77216231:77216296:77216335:77216348

0.1699

1.7738e-02

1.5088e-15

0.4280

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Dendritic_cells_activated

GSVA_HALLMARK_NOTCH_SIGNALING

chr14:31093482-31096121:+

KIRC

EER

MEX

ENSG00000129657.10

chr17

77215922:77215948:77216062:77216140:77216140:77216296:77216335:77216802

0.1641

1.9797e-02

2.4328e-15

0.4251

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Dendritic_cells_activated

GSVA_HALLMARK_NOTCH_SIGNALING

chr14:31093482-31096121:+

KIRC

EER

MEX

ENSG00000129657.10

chr17

77215922:77215948:77216062:77216140:77216218:77216296:77216335:77216802

0.1641

1.9797e-02

2.4328e-15

0.4251

DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;NOP56;NOP58;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM47;SRSF1;SRSF3;SRSF7;TARDBP;U2AF2;YTHDC1

Dendritic_cells_activated

GSVA_HALLMARK_NOTCH_SIGNALING

More results

Top

5. Enriched editing regions and immune infiltration for AP4S1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr14:31093482-31096121:+	BRCA	EER	B_cells_naive	5.5109e-03	-0.0931
ENSG00000100478.13,AP4S1	BRCA	EAG	B_cells_naive	5.7491e-03	-0.0927
chr14:31093482-31096121:+	CESC	EER	Monocytes	7.3114e-04	0.2236
ENSG00000100478.13,AP4S1	CESC	EAG	Monocytes	7.3114e-04	0.2236
chr14:31093482-31096121:+	COAD	EER	T_cells_CD4_naive	3.5874e-02	-0.2156
ENSG00000100478.13,AP4S1	COAD	EAG	Dendritic_cells_activated	2.0708e-02	0.2358
chr14:31093482-31096121:+	DLBC	EER	Mast_cells_resting	5.1082e-03	0.4149
ENSG00000100478.13,AP4S1	DLBC	EAG	Mast_cells_resting	5.1082e-03	0.4149
chr14:31093482-31096121:+	ESCA	EER	Neutrophils	1.6007e-02	0.1945
ENSG00000100478.13,AP4S1	ESCA	EAG	Neutrophils	1.3854e-02	0.1980
chr14:31093482-31096121:+	GBM	EER	Macrophages_M1	3.2724e-02	0.1705
ENSG00000100478.13,AP4S1	GBM	EAG	Macrophages_M1	3.2550e-02	0.1707
chr14:31093482-31096121:+	HNSC	EER	Eosinophils	3.8004e-03	-0.1568
ENSG00000100478.13,AP4S1	HNSC	EAG	Eosinophils	3.9024e-03	-0.1564
chr14:31093482-31096121:+	KICH	EER	T_cells_CD8	2.1885e-02	0.2884
ENSG00000100478.13,AP4S1	KICH	EAG	T_cells_CD8	2.1885e-02	0.2884
chr14:31093482-31096121:+	KIRC	EER	T_cells_regulatory_(Tregs)	2.6211e-05	0.2252
ENSG00000100478.13,AP4S1	KIRC	EAG	T_cells_regulatory_(Tregs)	7.6306e-06	0.2394
chr14:31093482-31096121:+	KIRP	EER	Dendritic_cells_activated	2.3323e-02	0.1426
ENSG00000100478.13,AP4S1	KIRP	EAG	Dendritic_cells_activated	2.3813e-02	0.1421
chr14:31093482-31096121:+	LAML	EER	Macrophages_M1	1.6006e-03	0.2898
ENSG00000100478.13,AP4S1	LAML	EAG	Macrophages_M1	1.4686e-03	0.2908
chr14:31093482-31096121:+	LGG	EER	Macrophages_M2	1.0436e-05	0.1912
ENSG00000100478.13,AP4S1	LGG	EAG	Macrophages_M2	9.1493e-06	0.1924
chr14:31093482-31096121:+	LIHC	EER	Monocytes	6.9189e-03	0.2340
ENSG00000100478.13,AP4S1	LIHC	EAG	Monocytes	8.9818e-03	0.2258
chr14:31093482-31096121:+	LUAD	EER	T_cells_CD4_memory_resting	2.7739e-02	-0.1102
ENSG00000100478.13,AP4S1	LUAD	EAG	T_cells_CD4_memory_resting	2.7522e-02	-0.1103
chr14:31093482-31096121:+	LUSC	EER	Macrophages_M2	7.6581e-03	-0.1417
ENSG00000100478.13,AP4S1	LUSC	EAG	Macrophages_M2	1.0273e-02	-0.1362
chr14:31093482-31096121:+	OV	EER	T_cells_CD8	2.8685e-03	0.1766
ENSG00000100478.13,AP4S1	OV	EAG	T_cells_CD8	2.5735e-03	0.1785
chr14:31093482-31096121:+	PCPG	EER	Plasma_cells	3.8182e-03	0.2188
ENSG00000100478.13,AP4S1	PCPG	EAG	Plasma_cells	4.1635e-03	0.2168
chr14:31093482-31096121:+	READ	EER	Mast_cells_activated	2.3995e-02	0.4112
ENSG00000100478.13,AP4S1	READ	EAG	Mast_cells_activated	2.3995e-02	0.4112
chr14:31093482-31096121:+	SARC	EER	NK_cells_activated	1.1500e-02	-0.1762
ENSG00000100478.13,AP4S1	SARC	EAG	NK_cells_activated	1.1742e-02	-0.1753
chr14:31093482-31096121:+	SKCM	EER	Mast_cells_activated	4.0913e-02	0.1142
ENSG00000100478.13,AP4S1	SKCM	EAG	Mast_cells_activated	3.9887e-02	0.1148
chr14:31093482-31096121:+	STAD	EER	B_cells_naive	7.7992e-03	-0.1587
ENSG00000100478.13,AP4S1	STAD	EAG	B_cells_naive	2.6720e-02	-0.1292
chr14:31093482-31096121:+	TGCT	EER	T_cells_CD8	1.4011e-02	0.2072
ENSG00000100478.13,AP4S1	TGCT	EAG	B_cells_naive	3.5034e-02	-0.1783
chr14:31093482-31096121:+	THCA	EER	Dendritic_cells_resting	4.0268e-05	0.1825
ENSG00000100478.13,AP4S1	THCA	EAG	Dendritic_cells_resting	3.9486e-05	0.1827
chr14:31093482-31096121:+	THYM	EER	T_cells_CD4_naive	6.0215e-05	-0.3651
ENSG00000100478.13,AP4S1	THYM	EAG	T_cells_CD4_naive	6.0772e-05	-0.3649

Top

6. Enriched editing regions and immune gene sets for AP4S1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000100478.13,AP4S1	BLCA	GSVA_HALLMARK_GLYCOLYSIS	EAG	1.1359e-02	0.1670
chr14:31093482-31096121:+	BLCA	GSVA_HALLMARK_GLYCOLYSIS	EER	1.0969e-02	0.1682
chr14:31093482-31096121:+	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.5298e-08	0.1857
ENSG00000100478.13,AP4S1	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.8930e-08	0.1873
chr14:31093482-31096121:+	CESC	GSVA_HALLMARK_DNA_REPAIR	EER	1.2345e-02	-0.1666
ENSG00000100478.13,AP4S1	CESC	GSVA_HALLMARK_DNA_REPAIR	EAG	1.2345e-02	-0.1666
chr14:31093482-31096121:+	CHOL	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.5043e-02	0.4127
ENSG00000100478.13,AP4S1	CHOL	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	4.7858e-02	0.4079
ENSG00000100478.13,AP4S1	COAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	1.5473e-02	-0.2465
chr14:31093482-31096121:+	COAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	3.3432e-02	-0.2185
chr14:31093482-31096121:+	DLBC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	7.2764e-03	0.3991
ENSG00000100478.13,AP4S1	DLBC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	7.2764e-03	0.3991
chr14:31093482-31096121:+	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.8089e-03	0.2268
ENSG00000100478.13,AP4S1	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	6.0292e-03	0.2204
chr14:31093482-31096121:+	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.9459e-02	0.1738
ENSG00000100478.13,AP4S1	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.8732e-02	0.1746
ENSG00000100478.13,AP4S1	KICH	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	6.9923e-03	-0.3366
chr14:31093482-31096121:+	KICH	GSVA_HALLMARK_MYC_TARGETS_V1	EER	6.9923e-03	-0.3366
chr14:31093482-31096121:+	KIRC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	3.3152e-04	-0.1930
ENSG00000100478.13,AP4S1	KIRC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	3.2580e-04	-0.1932
chr14:31093482-31096121:+	KIRP	GSVA_HALLMARK_UV_RESPONSE_DN	EER	3.7043e-04	-0.2221
ENSG00000100478.13,AP4S1	KIRP	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	3.6839e-04	-0.2222
ENSG00000100478.13,AP4S1	LAML	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	1.6385e-02	0.2215
chr14:31093482-31096121:+	LAML	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	1.6769e-02	0.2217
chr14:31093482-31096121:+	LGG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	1.5784e-11	-0.2889
ENSG00000100478.13,AP4S1	LGG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	5.2829e-11	-0.2815
ENSG00000100478.13,AP4S1	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	6.4497e-03	0.2351
chr14:31093482-31096121:+	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	6.2698e-03	0.2368
chr14:31093482-31096121:+	LUAD	GSVA_HALLMARK_APOPTOSIS	EER	4.7108e-02	0.0995
ENSG00000100478.13,AP4S1	LUSC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.4381e-02	-0.1300
chr14:31093482-31096121:+	LUSC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.5356e-02	-0.1289
chr14:31093482-31096121:+	MESO	GSVA_HALLMARK_APICAL_SURFACE	EER	7.0302e-03	0.3532
ENSG00000100478.13,AP4S1	MESO	GSVA_HALLMARK_APICAL_SURFACE	EAG	7.0302e-03	0.3532
ENSG00000100478.13,AP4S1	OV	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.6129e-03	0.1866
chr14:31093482-31096121:+	OV	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.5985e-03	0.1868
chr14:31093482-31096121:+	PAAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	4.4197e-02	0.1674
ENSG00000100478.13,AP4S1	PAAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	3.3992e-02	0.1756
ENSG00000100478.13,AP4S1	PCPG	GSVA_HALLMARK_E2F_TARGETS	EAG	2.2815e-03	-0.2305
chr14:31093482-31096121:+	PCPG	GSVA_HALLMARK_E2F_TARGETS	EER	2.2283e-03	-0.2310
ENSG00000100478.13,AP4S1	PRAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	3.2167e-04	-0.1735
chr14:31093482-31096121:+	PRAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	4.3507e-04	-0.1697
ENSG00000100478.13,AP4S1	READ	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.4870e-02	0.4404
chr14:31093482-31096121:+	READ	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	1.4870e-02	0.4404
ENSG00000100478.13,AP4S1	SARC	GSVA_HALLMARK_HYPOXIA	EAG	1.8205e-03	0.2160
chr14:31093482-31096121:+	SARC	GSVA_HALLMARK_HYPOXIA	EER	2.2038e-03	0.2127
chr14:31093482-31096121:+	STAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.2889e-03	0.1914
ENSG00000100478.13,AP4S1	STAD	GSVA_HALLMARK_ADIPOGENESIS	EAG	7.6544e-03	0.1553
ENSG00000100478.13,AP4S1	TGCT	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	9.3955e-06	0.3647
chr14:31093482-31096121:+	TGCT	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	8.0110e-06	0.3674
chr14:31093482-31096121:+	THCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	2.3338e-18	0.3773
ENSG00000100478.13,AP4S1	THCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	2.4256e-18	0.3771
chr14:31093482-31096121:+	THYM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	6.5401e-07	0.4443
ENSG00000100478.13,AP4S1	THYM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	6.6705e-07	0.4440
ENSG00000100478.13,AP4S1	UCEC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.2520e-02	0.2121
chr14:31093482-31096121:+	UCEC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.1772e-02	0.1836
chr14:31093482-31096121:+	UCS	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.3573e-02	0.3695
ENSG00000100478.13,AP4S1	UCS	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.3573e-02	0.3695
chr14:31093482-31096121:+	UVM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.6360e-02	0.2998
ENSG00000100478.13,AP4S1	UVM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	3.6360e-02	0.2998

Top

7. Enriched editing regions and drugs for AP4S1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000100478.13,AP4S1	BLCA	Gefitinib	EAG	9.1096e-03	-0.1720
chr14:31093482-31096121:+	BLCA	Gefitinib	EER	7.3903e-03	-0.1770
chr14:31093482-31096121:+	BRCA	CCT007093	EER	4.2328e-07	0.1688
ENSG00000100478.13,AP4S1	BRCA	CCT007093	EAG	3.8216e-07	0.1695
ENSG00000100478.13,AP4S1	CESC	Midostaurin	EAG	6.3194e-03	0.1815
chr14:31093482-31096121:+	CESC	Midostaurin	EER	6.3194e-03	0.1815
ENSG00000100478.13,AP4S1	CHOL	EHT.1864	EAG	2.5726e-02	0.4543
chr14:31093482-31096121:+	CHOL	Imatinib	EER	2.3121e-02	-0.4618
ENSG00000100478.13,AP4S1	COAD	Gemcitabine	EAG	3.1579e-03	-0.2983
chr14:31093482-31096121:+	COAD	Erlotinib	EER	7.2351e-04	-0.3409
chr14:31093482-31096121:+	DLBC	GDC0941	EER	3.0670e-03	0.4363
ENSG00000100478.13,AP4S1	DLBC	GDC0941	EAG	3.0670e-03	0.4363
chr14:31093482-31096121:+	ESCA	BI.D1870	EER	2.6218e-03	-0.2416
ENSG00000100478.13,AP4S1	ESCA	AS601245	EAG	3.3687e-03	0.2349
chr14:31093482-31096121:+	GBM	CGP.082996	EER	1.0094e-04	-0.3053
ENSG00000100478.13,AP4S1	GBM	CGP.082996	EAG	1.0096e-04	-0.3053
ENSG00000100478.13,AP4S1	HNSC	Bryostatin.1	EAG	7.8018e-04	-0.1816
chr14:31093482-31096121:+	HNSC	Bryostatin.1	EER	7.7146e-04	-0.1818
ENSG00000100478.13,AP4S1	KICH	JNJ.26854165	EAG	2.7310e-03	-0.3714
chr14:31093482-31096121:+	KICH	JNJ.26854165	EER	2.7310e-03	-0.3714
chr14:31093482-31096121:+	KIRC	CI.1040	EER	4.8547e-06	-0.2443
ENSG00000100478.13,AP4S1	KIRC	CI.1040	EAG	5.9382e-07	-0.2661
ENSG00000100478.13,AP4S1	KIRP	AZD6482	EAG	2.1584e-05	0.2636
chr14:31093482-31096121:+	KIRP	AZD6482	EER	1.8626e-05	0.2656
ENSG00000100478.13,AP4S1	LGG	Bortezomib	EAG	6.5209e-16	-0.3430
chr14:31093482-31096121:+	LGG	Bortezomib	EER	2.8939e-16	-0.3469
chr14:31093482-31096121:+	LIHC	Bexarotene	EER	1.4061e-03	0.2752
ENSG00000100478.13,AP4S1	LIHC	Bexarotene	EAG	9.9133e-04	0.2824
chr14:31093482-31096121:+	LUAD	AUY922	EER	1.9608e-02	-0.1168
ENSG00000100478.13,AP4S1	LUAD	AUY922	EAG	2.0781e-02	-0.1157
ENSG00000100478.13,AP4S1	LUSC	KU.55933	EAG	2.4982e-04	-0.1935
chr14:31093482-31096121:+	LUSC	KU.55933	EER	2.1161e-04	-0.1960
chr14:31093482-31096121:+	MESO	CCT018159	EER	1.0118e-02	-0.3380
ENSG00000100478.13,AP4S1	MESO	CCT018159	EAG	1.0118e-02	-0.3380
ENSG00000100478.13,AP4S1	OV	AZD.2281	EAG	4.5742e-03	-0.1684
chr14:31093482-31096121:+	OV	AZD.2281	EER	5.1898e-03	-0.1660
ENSG00000100478.13,AP4S1	PAAD	GSK269962A	EAG	1.8533e-02	-0.1960
chr14:31093482-31096121:+	PAAD	GSK269962A	EER	2.3549e-02	-0.1893
chr14:31093482-31096121:+	PCPG	FH535	EER	2.1799e-03	0.2315
ENSG00000100478.13,AP4S1	PCPG	FH535	EAG	2.1583e-03	0.2317
chr14:31093482-31096121:+	PRAD	Embelin	EER	5.9742e-03	0.1330
ENSG00000100478.13,AP4S1	PRAD	Embelin	EAG	7.3881e-03	0.1296
ENSG00000100478.13,AP4S1	SARC	GSK269962A	EAG	2.3633e-06	-0.3220
chr14:31093482-31096121:+	SARC	GSK269962A	EER	3.0451e-06	-0.3194
chr14:31093482-31096121:+	SKCM	A.770041	EER	1.1910e-02	-0.1402
ENSG00000100478.13,AP4S1	SKCM	A.770041	EAG	1.2854e-02	-0.1387
ENSG00000100478.13,AP4S1	STAD	Doxorubicin	EAG	1.6664e-03	0.1826
chr14:31093482-31096121:+	STAD	DMOG	EER	2.0831e-04	0.2199
chr14:31093482-31096121:+	TGCT	AZ628	EER	2.3200e-08	-0.4506
ENSG00000100478.13,AP4S1	TGCT	AZ628	EAG	2.3953e-07	-0.4200
chr14:31093482-31096121:+	THCA	CI.1040	EER	4.3959e-27	-0.4563
ENSG00000100478.13,AP4S1	THCA	CI.1040	EAG	4.4379e-27	-0.4563
ENSG00000100478.13,AP4S1	THYM	BAY.61.3606	EAG	1.2386e-08	0.5004
chr14:31093482-31096121:+	THYM	BAY.61.3606	EER	1.2037e-08	0.5008
chr14:31093482-31096121:+	UCEC	JNK.9L	EER	8.1274e-06	0.3709
ENSG00000100478.13,AP4S1	UCEC	AZD6244	EAG	1.1979e-06	-0.3996
ENSG00000100478.13,AP4S1	UCS	GSK.650394	EAG	5.2103e-03	-0.4140
chr14:31093482-31096121:+	UCS	GSK.650394	EER	5.2103e-03	-0.4140
ENSG00000100478.13,AP4S1	UVM	BMS.754807	EAG	8.7000e-03	0.3709
chr14:31093482-31096121:+	UVM	BMS.754807	EER	8.7000e-03	0.3709

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType